CND261
TMP-05062025-1
Phase 2 small_molecule active
Quick answer
CND261 for Active, treatment refractory, ANCA-IgG-positive associated vasculitis is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Active, treatment refractory, ANCA-IgG-positive associated vasculitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active